替诺福韦与恩替卡韦对乙肝相关肝癌术后复发的影响
韩国历史性队列纳入1695例乙肝相关肝癌根治性肝切除术后患者,比较替诺福韦(TDF)与恩替卡韦(ETV)治疗。倾向评分匹配和多变量校正分析显示,TDF组肝癌复发风险显著低于ETV组,总生存率更高。
要点
- TDF组肝癌复发风险较ETV组降低18%(HR 0.82,95%CI 0.68-0.98,P=0.03)。
- TDF对术后早期(<2年)和晚期(≥2年)复发均为独立保护因素。
核心结论
- 乙肝相关肝癌根治性肝切除术后,TDF治疗较ETV治疗与更低的肝癌复发风险和更好的总生存相关。
研究设计与样本
- 韩国2010至2018年历史性队列研究,纳入1695例因乙肝相关肝癌行根治性肝切除术的连续患者,其中ETV组813例,TDF组882例。
- 采用倾向评分匹配和多变量校正Cox回归分析,从肝切除术日期起比较两组肝癌复发和总生存。
主要发现
- 中位随访37.6个月期间,561例(33.1%)出现肝癌复发,144例(8.4%)死亡,22例(1.3%)接受肝移植。
- 倾向评分匹配分析显示,TDF组无复发生存率(P=0.02)和总生存率(P=0.03)均显著高于ETV组。
- 多变量校正分析显示,TDF组肝癌复发风险显著低于ETV组(HR 0.82,95%CI 0.68-0.98,P=0.03)。
- 多变量校正分析显示,TDF组死亡或移植风险显著低于ETV组(HR 0.62,95%CI 0.44-0.88,P=0.01)。
- TDF治疗是术后早期复发(<2年;HR 0.79,P=0.03)和晚期复发(≥2年;HR 0.68,P=0.03)的独立保护因素。
关键数值与推荐
- 研究人群为巴塞罗那临床肝癌分期0期或A期的乙肝相关肝癌患者,均接受根治性肝切除术。
- TDF组相对于ETV组的肝癌复发HR为0.82(95%CI 0.68-0.98,P=0.03),死亡或移植HR为0.62(95%CI 0.44-0.88,P=0.01)。
临床怎么用
- 对于乙肝相关肝癌根治性肝切除术后需抗病毒治疗的患者,选择TDF可能较ETV更有利于降低肝癌复发风险。
- 该研究为观察性证据,临床决策需结合患者个体情况、肾功能和骨代谢等安全性因素综合评估。
局限性
- 研究为历史性队列设计,非随机对照试验,可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Studies have suggested that tenofovir disoproxil fumarate (TDF) treatment is associated with a significantly lower risk of hepatocellular carcinoma (HCC) occurrence when compared with entecavir (ETV) therapy in patients with chronic hepatitis B. We aimed to compare HCC recurrence and survival of patients treated with TDF or ETV after surgical resection for hepatitis B virus (HBV)-related HCC. APPROACH AND RESULTS: This historical cohort study included 1,695 consecutive patients treated with ETV (n = 813) or TDF (n = 882) after curative-intent hepatectomy for HBV-related HCC of Barcelona Clinic Liver Cancer stage 0 or A in Korea between 2010 and 2018. HCC recurrence and overall survival of patients were compared between ETV and TDF groups by propensity score-matched and multivariable-adjusted Cox regression analyses from the date of hepatectomy for HCC. The mean age of the study patients was 54.8 years, and 1,294 patients (76.3%) were male. During the median follow-up duration of 37.6 months with continued ETV or TDF therapy, 561 (33.1%) patients developed HCC recurrence, 144 (8.4%) died, and 22 (1.3%) received liver transplant. Compared with ETV, TDF therapy was associated with significantly higher recurrence-free (P = 0.02) and overall survival (P = 0.03) rates by propensity score-matched analysis. By multivariable-adjusted analysis, the TDF group was associated with significantly lower rates of HCC recurrence (hazard ratio [HR], 0.82; 95% confidence interval, 0.68-0.98; P = 0.03), and death or transplantation (HR, 0.62; 95% confidence interval, 0.44-0.88; P = 0.01). TDF therapy was an independent protective factor for both early (<2 years; HR, 0.79; P = 0.03) and late (≥2 years; HR, 0.68; P = 0.03) postoperative HCC recurrence. CONCLUSIONS: Among patients who underwent curative hepatectomy for HBV-related HCC, TDF therapy was associated with a significantly lower risk of HCC recurrence and better overall patient survival compared with ETV therapy.
引用
- Choi J, Jo C, Lim YS, et al. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology. 2020. PMID: 32324905. doi:10.1002/hep.31289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。